-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-518438-94-00
4
2025-10-24
Heart failure
-
2024-517140-65-00
9
2025-10-23
Multiple Myeloma (MM).
-
2024-514110-12-00
7
2025-10-22
Thyroid Eye Disease
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-520355-25-00
5
2025-10-10
generalized myasthenia gravis
-
2024-515682-34-00
5
2025-10-06
Chronic migraine
-
2024-515715-22-00
5
2025-10-06
Episodic migraine
-
2024-518714-31-00
5
2025-10-03
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
-
2024-519736-17-00
4
2025-10-03
Hidradenitis Suppurativa
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-512177-27-01
5
2025-09-29
High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invas
-
2024-517866-40-00
4
2025-09-29
Moderate-to-severe Asthma
-
2025-520473-40-00
4
2025-09-29
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-519875-24-00
5
2025-09-26
Carcinoid syndrome
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-517633-40-00
5
2025-09-18
Hidradenitis Suppurativa
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2024-514186-18-00
1
2025-09-09
Systemic Lupus Erythematosus